Latest Commercialization News

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.

Cromwell Property Group has launched a major office development in Canberra’s Barton precinct with a long-term lease to a key Commonwealth Government department, alongside a strategic debt refinancing.

Nanoveu Limited has raised A$2 million through a strategic placement to accelerate the commercialisation of its 16nm ECS-DoT chip and expand its EMASS modular AIoT platform, positioning the company for global growth.

AML3D Limited has confirmed it complied with ASX continuous disclosure rules regarding its recent Letter of Intent with the US Navy, clarifying the timing of its awareness and announcement.

Buru Energy has agreed to sell its hydrogen-focused subsidiary 2H Resources and non-core Canning Basin assets to Koloma Australia for up to AUD 2 million, marking a strategic pivot towards its Rafael Gas Project.

Renascor Resources has secured an option agreement for land near its Siviour graphite deposit, finalising a critical step in supporting its upstream mining and processing operations. This move advances the company’s Battery Anode Material project readiness with accommodation planned for construction and operational staff.

Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.

G50 Corp has confirmed a significant new precious metals discovery at its Golconda Project in Arizona, revealing extensive gold, silver, and zinc mineralization from its latest drilling program. The results also highlight notable gallium mineralization, underscoring the project's strategic value.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

Osmond Resources has significantly expanded its Orion EU Critical Minerals Project by 160%, with promising assay results and a planned drilling program to confirm mineral continuity. The company is positioning itself to benefit from strong EU demand for rare earths, titanium, and silicon metals.

Race Oncology has secured key ethics approvals to launch its Phase 1 RC220 trial at two major Hong Kong hospitals, marking a strategic expansion beyond Australia to accelerate patient recruitment and explore cardioprotective benefits.